Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | ESMO 2018 Congress
Specialties >>
Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Biosimilars
MORE >>
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast Cancer
August 30, 2018
Francisco J. Esteva, MD, PhD, discusses the current data surrounding CT-P6 demonstrating its potential as a biosimilar for trastuzumab in the United States.
Read more >>
Second Filgrastim Biosimilar Granted FDA Approval
July 24, 2018
PFS With MYL-1401O Regimen Similar to Trastuzumab at 48 Weeks in HER2-Positive Metastatic Breast Cancer
June 08, 2018
Epoetin Alfa Biosimilar Approved by FDA for Treatment of Anemia
May 15, 2018
Trump Announces Blueprint to Lower Drug Costs in US
May 14, 2018
Videos
MORE >>
Impact of Biosimilars on Oncology
Latest Journal
All Journals >>
Evolving Paradigms
Non-Small Cell Lung Cancer
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
MORE >>
JTT Articles
The Role of JAK2 Inhibition in Polycythemia Vera
Current and Emerging Immunotherapy Strategies in Advanced Urothelial Cancers
Small Cell Transformation: An Increasingly Common Mechanism of Resistance in EGFR-Mutated Lung Cancer
>> View Peer-Reviewed Articles
